Dr. Juan Carlos Roa S.

Cargo


Jefe del Departamento de Anatomía Patológica

Profesor Titular

Teléfono


(+56)223543889

(+56)223541061

Contacto


jcroa@med.puc.cl

Formación Pregrado:

Médico Cirujano, Licenciado en Medicina,  Universidad de La Frontera, Chile, 1985 – 1991.

 

Formación Postgrado:

Programa de formación en Anatomía Patológica Especialista en Anatomía Patológica, Pontificia Universidad Católica de Chile, 1992 – 1995.

Fellowship «Biologia molecular», Luisiana State University, New Orleans, USA, 1997 – 1999

Master en Oncología Molecular, Centro Nacional de Investigación Oncológica CNIO, Chile, 2010 – 2012

Líneas de Investigación:

  1. Patología Quirúrgica de la Vesícula Biliar.
  2. Búsqueda y validación de Blancos para Terapia Especifica dirigida  en tumores digestivos (Colon, Estómago, Vesícula biliar).
  3. Carcinogénesis de la Vesícula biliar. (Inflamación y cáncer de vesícula biliar)
  4. Búsqueda y validación de biomarcadores ( proteómicos, miRNA genéticos) de  diagnóstico, predisposición genética, pronóstico, predicción de respuesta a terapia de cáncer de vesícula biliar.
  5. Exosomas como  biomarcador en cáncer de vesícula biliar.
  6. Validación de programa de biopsia líquida en Oncología.
  7. Biobancos

Proyectos de Investigación:

  1. 2009-2013 VALIDATION OF MTOR METABOLIC PATHWAY INACTIVATION FOR GALLBLADDER CANCER TARGETED THERAPY. Número FONDECYT Investigador Responsable: ( CLP 200.000.000)
  2. 2013-2015 PYROSEQUENCING PLATFORM FOR EPIGENETIC AND POLYMORPHISM RESEARCH. Investigador Responsable FONDEQUIP PI (CLP 93.000.000)
  3. 2013-2017 IDENTIFICATION AND VALIDATION OF EARLY DIAGNOSTIC GALLBLADDER CANCER BIOMARKERS IN CHILEAN PATIENTS BY QUANTITATIVE PROTEOMICS. A PHASE 1 AND 2 BIOMARKER VALIDATION TRIAL.»Fondecyt Regular Investigador Responsable ( CLP 198.000.000)
  4. (2012-2014) PLATAFORMA DE ESTUDIOS PRECLÍNICOS DE XENOTRANSPLANTES DE TEJIDOS METASTÁTICOSHUMANOS PARA LA EVALUACIÓN DE SENSIBILIDAD A DROGAS ANTICANCERÍGENAS. FONDEF ideas CA12i10333 (Director alterno) (CLP 180.000.000)
  5. 2011-2014 CENTRO DE EXCELENCIA EN STUDIOS GENETICOS E INMUNOLÓGICOS (CEGIN) Corfo Innova Co Pi  ( subdirector)  (CLP 450.000.000)
  6. (2012- 2015) IMPROVING THE PRODUCTION OF PHENYLPROPANOIDS WITH ANTIOXIDANT ACTIVITY IN HIGHBUSH BLUEBERRY (VACCINIUM CORYMBOSUM L.) USING METHYL JASMONATE AND UV-B RADIATION AND ITS EFFECT ON GASTRIC cancer chemoprevention. Co investigador Fondecyt 1120917 CoPI. (CLP 150.000.000)
  7. 2012-2013 A PILOT STUDY OF GALLBLADDER CANCER IN CHILE NCI- Chile. Chilean Co-Pi. (USD 10.000)
  8. 2012- 2015 PROYECTO BIOBANCO FACULTAD MEDICINA Hospital Sotero del Rio. Pontificia Universidad catolica de Chile.   (PUC)
  9. 2013-2018 Fondap. Centro de Estudios Avanzados de Enfermedades Crónicas (ACCDIS). Investigador asociado. 
  10. 2015-2023Proyecto  NCI Chile Biliary Longitudinal Study (Chile BiLS)  intramural CHILE  Coinvestigador Chile.  Coordinador área de Patología.
  11. 2015 – 2020 Proyecto  NCI RO1 “Lifetime arsenic exposure and low dose cancer risks in a unique area in Chile”. Coinvestigador  CA Pulmon.
  12. (2013-2018)Identification of activated tyrosine kinase signaling pathways associated with drug-resistant phenotype of gallbladder cancer by SILAC-based quantitative phosphoproteomics. Fondecyt Iniciacion Patrcia Garcia ( Patrocinante).
  13. (2013-2016)Identification and validation of prognostic biomarkers and potential therapeutic targets of the Hippo signaling pathway in gallbladder cancer patients.  Fondecyt Postdoctorado. Carolina Bizama ( tutor)
  14. (2013-2016)Transcriptomic profiling of gallbladder cancer progression. Fondecyt Postdoctorado Jaime Espinoza  ( Tutor)
  15. (2015-2018) Proteomic signature of gallbladder cancer secreted exosomes: a dynamic approach todelineate their potential role during malignant progression and their clinical relevance as novel reservoir of circulating biomarkers. Fondecyt Regular Coinvestigador.

Publicaciones:

Año 2015 (23) 

  1. BENEFICIAL EFFECTS OF MINERALOCORTICOID RECEPTOR BLOCKADE IN EXPERIMENTAL NON-ALCOHOLIC STEATOHEPATITIS Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P,Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M.. Liver Int. 2015 Feb 2. [Epub ahead ofprint] PubMed PMID: 25646700. ISI  4,85
  2. CALCIUM CALMODULIN DEPENDENT KINASE KINASE 2 – A POTENTIAL THERAPEUTIC TARGET FOR GASTRIC ADENOCARCINOMA Yashwanth Subbannayya1,2,3*, Nazia Syed1,4*, Remya Raja1*, Arivusudar Marimuthu1, Nandini Sahasrabuddhe1,5, Sneha M. Pinto1,5, Srikanth Srinivas Manda1,6, Santosh Renuse1,7, Manju H. C.1,8, Mohammed Abdul Lateef Zameer8, Jyoti Sharma1,5, Kotteazeth Srikumar4, Juan Carlos Roa9, M. Vijaya Kumar10, K. V. Veerendra Kumar10, T. S. Keshava Prasad1,5,6,7, Girija Ramaswamy3, Rekha Vijay Kumar8 , Akhilesh Pandey11-15, Harsha Gowda1$, Aditi Chatterjee1$Cancer Biol Ther. 2015 Feb;16(2):336-45. doi: 10.4161/15384047.2014.972264. ISI 3,07
  3. MACROPHAGE MIGRATION INHIBITORY FACTOR – A THERAPEUTIC TARGET IN GALLBLADDER CÁNCER. Tejaswini SubbannayyaPamela Leal RojasMustafa A BarbhuiyaRemya RajaSantosh RenuseGajanan SatheSneha Maria PintoNazia SyedVishalakshi NanjappaArun H PatilPatricia GarciaNandini A SahasrabuddheBipin NairRafael Guerrero-PrestonSanjay NavaniPramod K TiwariVani SantoshDavid SidranskyT S Keshava PrasadHarsha GowdaJuan Carlos Roa Akhilesh PandeyAditi Cancer Biol Ther.2015;16(2):336-45. ISI 3,07
  4. PATHOLOGIC EVALUATION AND REPORTING OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMNs) OF THE PANCREAS AND OTHER TUMORAL INTRAEPITHELIAL NEOPLASMS OF PANCREATOBILIARY TRACT: RECOMMENDATIONS OF VERONA CONSENSUS MEETINGVolkan Adsay1, Mari Mino-Kenudson2, Toru Furukawa3, Olca Basturk4, Giuseppe Zamboni5, Giovanni Marchegiani6, Claudio Bassi7, Roberto Salvia7, Giuseppe Malleo7, Salvatore Paiella7, Christopher L.Wolfgang8, Hanno Matthaei9, G. Johan Offerhaus10, Mustapha Adham11, Marco J. Bruno12, Michelle Reid1, Alyssa Krasinskas1, Günter Klöppel13, Nobuyuki Ohike14, Takuma Tajiri15, Kee-Taek Jang16, Juan Carlos Roa17, Peter Allen18, Carlos Fernández-del Castillo19, Jin-Young Jang20; David Klimstra4, Ralph H. Hruban21 Ann Surg. 2015 Mar 13. [Epub ahead of print] PubMedISI 8,3
  5. GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS ESTROGEN-MEDIATED EPIGENETIC REPRESSION OF METALLOTHIONEIN-1 GENE CLUSTER IN BREAST CANCER.Jadhav RR, Ye Z, Huang RL, Liu J, Hsu PY, Huang YW, Rangel LB, Lai HC, Roa JC, Kirma NB, Huang TH, Jin VX. Clin Epigenetics. 2015 Feb 24;7(1):13. doi: 10.1186/s13148-015-0045-9. eCollection 2015. PubMed PMID: 25763113; PubMed Central PMCID: PMC4355986. ISI 4,54
  6. MOLECULAR CLASSIFICATION OF GASTRIC CANCER: TOWARDS A PATHWAY-DRIVEN TARGETED THERAPY Riquelme Ismael,*, Saavedra Kathleen1*, Espinoza Jaime A2,3, Weber Helga1, García Patricia, Nervi Bruno, Garrido Marcelo, Corvalán Alejandro H, Roa Juan Carlos2,3,6 and Bizama Carolin Oncotarget in press  2105 ISI .6,36 *
  7. TARGETING SPECIFIC MOLECULAR PATHWAYS HOLDS PROMISE FOR ADVANCED GALLBLADDER CANCER THERAPY. Bizama C,  Garcia P,  Espinoza  Nervi B, Roa JC, Cancer Treat Rev. 2015 Mar;41(3):222-34 ISI 7,6*
  1. ASSOCIATION OF AFLATOXIN WITH GALLBLADDER CANCER IN CHILE Nogueira L, Foerster C, Groopman J, Egner P, Koshiol J, Ferreccio C.Gallbladder Cancer Chile Working Group.. 2015 May 26;313(20):2075-7. doi: 10.1001/jama.2015.4559. ISI 35.3
  2. LOSS OF EXPRESSION OF REPRIMO, A P53-INDUCED CELL CYCLE ARREST GENE, CORRELATES WITH INVASIVE STAGE OF TUMOR PROGRESSION AND P73 EXPRESSION IN GASTRIC CANCER Saavedra K, Valbuena J, Olivares W, Marchant MJ, Rodríguez A, Torres-Estay V, Carrasco-Avino G, Guzmán L, Aguayo F, Roa JC, Corvalán AH.. PLoS One. 2015 May 8;10(5): ISI 3,53*
  3. STAT3 REGULATES ERBB-2 EXPRESSION AND CO-OPTS ERBB-2 NUCLEAR FUNCTION TO INDUCE MIR-21 EXPRESSION, PDCD4 DOWNREGULATION AND BREAST CANCER METASTASIS. Patricia Elizalde, Leandro Venturutti, Lucia Romero, Alejandro Urtreger, María Chervo, Rosalía Cordo Russo, María Mercogliano, Gloria Inurrigarro, Matías Pereyra, Cecilia Proietti, Franco Izzo, María Díaz Flaqué, Victoria Sundblad, Juan Roa, Pablo Guszmán, Elisa Bal de Kier Joffé, Eduardo Charreau, and Roxana SchillaciOncogene in press  ISI 8.46
  4. EXPRESSION OF INSULIN-LIKE GROWTH FACTOR I RECEPTOR AS A BIOMARKER FOR PREDICTING PROGNOSIS IN BILIARY TRACT CANCER PATIENTS. Suzuki H, Roa JC, Kawamoto T, Ishige K, Wistuba II, Li D, Thomas MB, Shoda J.Mol Clin Oncol. 2015 May;3(3):464-470. Epub 2015 Feb 25. PubMed PMID: 26137252; PubMed Central PMCID: PMC4471625. NO ISI
  5. GALLBLADDER CANCER: EXPERT CONSENSUS STATEMENT. Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, Coimbra FJ, Jarnagin WR.HPB (Oxford). 2015 Aug;17(8):681-690. doi: 10.1111/hpb.12444. PubMed PMID: 26172135. ISI 2,68*
  6. [GENOTYPING OF HUMAN PAPILLOMAVIRUS IN WOMEN UNDER 25 YEARS OLD TREATED IN THE SCREENING PROGRAM FOR CERVICAL CANCER]. Melo A, Vásquez AM, Andana A, Matamala M, Pino T, Guzmán P, Hoffstetter R, Iii C, Brebi P, Roa JC Rev Chilena Infectol. 2014 Oct;31(5):542-8. doi: 10.4067/S0716-10182014000500005. Spanish. PubMed PMID: 25491452. ISI 0,494*
  7. -TUMOR LOCATION IS A STRONG PREDICTOR OF TUMOR PROGRESSION AND SURVIVAL IN T2 GALLBLADDER CANCER: AN INTERNATIONAL MULTICENTER STUDY IN PRESS ANNALS OF SURGERY. Shindoh J1,de Aretxabala X,Aloia TARoa JCRoa IZimmitti GJavle MConrad CMaru DMAoki TVigano LRibero DKokudo NCapussotti L,Vauthey JN. Ann Surg. 2015 Apr;261(4):733-9. doi: 10.1097/SLA.0000000000000728.  ISI 8,3
  8. GLOBAL PHOSPHOTYROSINE SURVEY IN TRIPLE-NEGATIVE BREAST CANCER REVEALS ACTIVATION OF MULTIPLE TYROSINE KINASE SIGNALING PATHWAYS Xinyan Wu1,2#, Muhammad Saddiq Zahari1,2#, Binyun Ma6, Ren Liu6, Santosh Renuse1,2,5, Nandini A Sahasrabuddhe1,2,5, Lily Chen3, Raghothama Chaerkady1,2, Min-Sik Kim1,2, Jun Zhong1,2, Christine Jelinek1,2, Mustafa A. Bharbuiya1,2,5, Pamela Leal-Rojas1,2,7, Yi Yang1,2, Manoj Kumar Kashyap1,2,5, Arivusudar Marimuthu1,2,5, Min Ling1, Mary Jo Fackler3, Vanessa Merino3, Zhen Zhang3, Cynthia A Zahnow3, Edward Gabrielson3,4, Vered Stearns3, Juan Carlos Roa7, Saraswati Sukumar3, Parkash S Gill6 and Akhilesh Pandey1,2,3,4* Oncotarget submmitteed ISI 6,4
  9. QUANTITATIVE PHOSPHOPROTEOMIC ANALYSIS OF IL-33-MEDIATED SIGNALING Pinto SM, Nirujogi RS, Rojas PL, Patil AH, Manda SS, Subbannayya Y, Roa JC,Chatterjee A, Prasad TS, Pandey A.. Proteomics. 2015 Jan;15(2-3):532-44. doi: 1002/pmic.201400303. PubMed PMID: 25367039. ISI 3,973
  10. TARGETING ERBB-2 NUCLEAR LOCALIZATION AND FUNCTION INHIBITS BREAST CANCER GROWTH AND OVERCOMES TRASTUZUMAB RESISTANCE Cordo Russo RI, Béguelin W, Díaz Flaqué MC, Proietti CJ, Venturutti L, Galigniana N, Tkach M, Guzmán P,Roa JC, O’Brien NA, Charreau EH, Schillaci R, Elizalde  Oncogene. 2014 Sep 1;0. doi: 10.1038/onc.2014.272. [ ISI 8,55
  11. EFFECTS OF c-FLIPL KNOCKDOWN IN CERVICAL UTERINE CARCINOMA CELL LINES Carmen G. Ili1, Priscilla Brebi1, Patricia Garcia1,2, Pamela Leal1, Jaime Lopez1, Oscar Tapia1, Pablo Letelier1, Helga Weber1, Juan C. Roa1,2*.In press a International Journal of Morphology In Press ISI 0,3*
  12. «HEREGULIN CO-OPTS PR TRANSCRIPTIONAL ACTION VIA STAT3 ROLE AS A COREGULATOR TO DRIVE CANCER GROWTH», Proeitti C Roa JC, Elizalde P In press Molecular Endocrinology ISI 4.022*
  13. LOW EXPRESSION OF ENT1 IS ASSOCIATED WITH POOR PROGNOSIS IN CHEMOTHERAPY-NAÏVE PT2 GALLBLADDER ADENOCARCINOMA PATIENTS Espinoza J , Garcia P, Nervi B , Roa JC Plos One ISI 3,5*
  14. «RAPAMYCIN AND WYE-354 SUPPRESS HUMAN GALLBLADDER CANCER XENOGRAFTS IN MICE» Riquelme Ismael,*, Saavedra Kathleen1*, Espinoza Jaime A2,3, Weber Helga1, García Patricia, Nervi Bruno, Garrido Marcelo, Corvalán Alejandro H, Roa Juan Carlos2,3,6 and Bizama Carolin Oncotarget in press 2015 ISI .6,36*
  15. MIR-101-2, MIR-125B-2 AND MIR-451A ACT AS POTENTIAL TUMOR SUPPRESSORS IN GASTRIC CANCER AND AGS CELLS THROUGH THE REGULATION IN THE PI3K/AKT/MTOR PATHWAY.  Ismael Riquelme1*, Oscar Tapia1*, Pamela Leal2, Alejandra Sandoval1, Matthew G. Varga3, Pablo Letelier4, Kurt Buchegger1, Carolina Bizama5, Jaime A. Espinoza5, Richard M. Peek3, Juan Carlos RoaCellular Oncology In press 3.032 July 2015. *
  16. THE ACTIVATED STATUS OF THE PI3K/AKT/MTOR PATHWAY IN TUMORAL TISSUES AND THREE CELL LINES OF GASTRIC CANCER. Ismael Riquelme1*, Oscar Tapia1*, Jaime A. Espinoza2, Pamela Leal3, Alejandra Sandoval1, Kurt Buchegger1, Carolina Bizama2, Patricia García2, Juan Carlos Araya1, Juan Carlos Roa2,4 International Journal of sciencies submmited July 2015 ISI 2,17

 

 Año 2014 (13)

  1. IMMUNOHISTOCHEMICAL ANALYSIS OF THE PI3K/AKT/mTOR PATHWAY IN GASTRIC CANCER: CORRELATION WITH CLINICOPATHOLOGICAL FEATURES AND CUMULATIVE SURVIVAL. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P, Roa JC. Virchows Arch. 2014 May 21. [Epub ahead of print] PubMed PMID: 24844205. DOI 10.1007/s00428-014-1588-4 ISI 2,676
  2. «HYPERMETHYLATION OF TUMOR SUPPRESSOR GENE P53 IN CHILEAN PATIENTS UNDER 15 YEARS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.» Melo A1, Artigas CG2, Fritz C1, Díaz P1, Muñoz S3, Brebi P1, Roa JC1-4.  Int. J. Morphol., 32(4):1243-1247, 2014.  http://dx.doi.org/10.4067/S0717-95022014000400019 ISI 0.2
  3. [GENOTYPING OF HUMAN PAPILLOMAVIRUS IN WOMEN UNDER 25 YEARS OLD TREATED IN THE SCREENING PROGRAM FOR CERVICAL CANCER]. Melo A, Vásquez AM, Andana A, Matamala M, Pino T, Guzmán P, Hoffstetter R, IIi C, Brebi P, Roa JC. Rev Chilena Infectol. 2014 Oct;31(5):542-8. doi: 10.4067/S0716-10182014000500005 (ISI 0,494)
  4. MIR-1 AND MIR-145 ACT AS TUMOR SUPPRESSOR MICRORNAS IN GALLBLADDER CANCERPablo Letelier1,2, Patricia García3, Pamela Leal1, Héctor Álvarez4, Carmen Ili1, Jaime López1 and Juan Carlos Roa1,3 Int J Clin Exp Pathol. 2014 Apr 15;7(5):1849-67. eCollection 2014 ISI 2,04
  5. IDENTIFICATION OF PROSAPOSIN AND TRANSGELIN AS POTENTIAL BIOMARKERS FOR GALLBLADDER CANCER USING QUANTITATIVE PROTEOMICS CORRESPONDING AUTHOR: Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, Shrivastav BR, Navani S, Leal P, Roa JC, Chaerkady R, Gupta S, Chatterjee A, Pandey A, Tiwari PK.Biochem Biophys Res Commun. 2014 Apr 18;446(4):863-9. doi: 10.1016/j.bbrc.2014.03.017. Epub 2014 Mar 20.ISI 2,4
  6. “EVALUATION OF ZAR1 AND SFRP4 METHYLATION STATUS AS POTENTIAL BIOMARKERS FOR DIAGNOSIS AND PROGRESSION IN CERVICAL CARCINOGENESIS: EXPLORATORY STUDY PHASE I”, Brebi P, Hoffstetter R, Andana A, Ili CG, Saavedra K, Viscarra T, Retamal J,Sanchez R, Roa JC  Biomarkers. 2014 May;19(3):181-8 DOI: 10.3109/1354750X.2013.867535 ISI 1.87 
  7. GENOME-WIDE METHYLATION PROFILING REVEALS ZINC FINGER PROTEIN 516 (ZNF516) AND FK-506-BINDING PROTEIN 6 (FKBP6) PROMOTERS FREQUENTLY METHYLATED IN CERVICAL NEOPLASIA, ASSOCIATED WITH HPV STATUS AND ETHNICITY IN A CHILEAN POPULATIONBrebi P, Maldonado L, Noordhuis MG, Ili C, Leal P, Garcia P, Brait M, Ribas J, Michailidi C, Perez J, Ethan Soudry, Oscar Tapia, Pablo Guzman, Sergio Muñoz, Leander Van Neste, Wim Van Criekinge, Rafael Irizarry, David Sidransky, Juan C Roa*, Rafael Guerrero-Preston *Epigenetics 2014; 9:0 – -1; PMID: 24241165; http://dx.doi.org/10.4161/epi.27120 ISI 4.9
  8. IMMUNOHISTOCHEMICAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR A INADVANCED GALLBLADDER CARCINOMA 1: Letelier P, Garcia P, Leal P, Ili C, Buchegger K, Riquelme I, Sandoval A, Tapia O, Roa JC.. Appl Immunohistochem Mol Morphol. 2014 Aug;22(7):530-6. doi: 10.1097/PAI.0b013e3182a318a9. ISI 2.012.
  9. SYNCHRONOUS ILEOCECALAND DUODENAL TUBERCULOSIS: CASE REPORT AND REVIEW OF THE LITERATURE. Villalon C, Quezada F, Hartmann J, Roa JC, Urrejola G. Int J bColorectal Dis. 2014 Aug;29(8):1027-8. doi: 10.1007/s00384-014-1894-y. Epub 2014 May 10. DOI 10.1007/s00384-014-1894-y ISI 2,415
  10. COMPLETE PATHOLOGICAL RESPONSE TO IMATINIB MESYLATE IN AN EXTRAINTESTINAL GASTROINTESTINAL STROMAL TUMOR Quezada N, Acevedo F, Marambio A, León F, Galindo H, Roa JC, Jarufe N.. Int J Surg Case Rep. 2014 Aug 5;5(10):681-685. doi: 10.1016/j.ijscr.2014.05.009.  NO ISI
  11. INTRACHOLECYSTIC PAPILLARY TUBULAR NEOPLASM OF THE GALLBLADDER WITH MICROINVASIVE CARCINOMA.S Balci, G Akkas, JC Roa, NV Adsay Pathology Case Reviews 19 (6), 283-288. ( NO ISI)
  12. EPIDEMIOLOGÍA DEL CÁNCER DE TIROIDES EN CHILE: RESULTADOS DEL ESTUDIO INCATIRJ Sapunar, S Muñoz, JC Roa Revista médica de Chile 2014 Sep;142(9):1099-105. doi: 10.4067/S0034-98872014000900002. ISI (0,304)
  13. HUMAN PAPILLOMA VIRUS FREQUENCY IN NON-GYNECOLOGICAL TUMORS IN THE ARAUCANÍA René Hoffstetter* ; Alejandra Andana* ; Pablo Guzmán* ; Carmen G. Ili* ; Javier Retamal* ; Bárbara Mora* ; Juan C. Roa*** & Raúl Sánchez** Region, Chile Int. J. Morphol., 32(4):1254-1260, 2014. http://dx.doi.org/10.4067/S0717-95022014000400021 (ISI 0.318)

 

Año 2013. (18)

  1. CMS: A WEB-BASED SYSTEM FOR VISUALIZATION AND ANALYSIS OF GENOME-WIDE METHYLATION DATA OF HUMAN CANCERS. Gu F, Doderer MS, Huang YW, Roa JC, Goodfellow PJ, Kizer EL, Huang TH, Chen Y.PLoS One. 2013 Apr 22;8(4): ISI 3,73
  2. INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF/CCN2) IN GALLBLADDER CANCER CELLS LEADS TO DECREASED GROWTH IN VITRO. Garcia P, Leal P, Ili C, Brebi P, Alvarez H, Roa JC. Int J Exp Pathol. 2013 Jun;94(3):195-202 ISI 2,6
  3. TREATMENT OF THE RESIDUAL CAVITY DURING HEPATIC HYDATIDOSIS SURGERY: A COHORT STUDY OF CAPITONNAGE VS. OMENTOPLASTY. Manterola C, Roa JC, Urrutia S; MINCIR Group. Surg Today. 2013 Apr 6. [Epub ahead of print] ISI 1,22
  4. IMMUNOHISTOCHEMICAL EXPRESSION OF PHOSPHO-MTOR IS ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH GALLBLADDER ADENOCARCINOMA.Leal P, García P, Sandoval A, Letelier P, Brebi P, Ili C, Alvarez H, Tapia O, Roa JC.Arch Pathol Lab Med. 2013 Apr;137(4):552-7.  ISI,2,5
  5. CELLULAR FLICE-LIKE INHIBITORY PROTEIN LONG FORM (C-FLIPL) OVEREXPRESSION IS RELATED TO CERVICAL CANCER PROGRESSION. Ili CG, Brebi P, Tapia O, Sandoval A, Lopez J, Garcia P, Leal P, Sidransky D, Guerrero-Preston R, Roa JC. Int J Gynecol Pathol. 2013 May;32(3):316-22 ISI 1,413
  6. NEOADJUVANT CHEMORADIATION THERAPY FOR BORDERLINE PANCREATIC ADENOCARCINOMA: REPORT OF TWO CASES. Galindo J, Gabrielli M, Guerra JF, Cassina JC, Garrido M, Jarufe N, Borghero Y, Madrid J, Zoroquiain P, Roa JC, Martínez J. World J Surg Oncol. 2013 Feb 5;11:37. ISI 1,12
  7. CONNECTIVE TISSUE GROWTH FACTOR IMMUNOHISTOCHEMICAL EXPRESSION IS ASSOCIATED WITH GALLBLADDER CANCER PROGRESSION.Garcia P, Leal P, Alvarez H, Brebi P, Ili C, Tapia O, Roa JC. Arch Pathol Lab Med. 2013 Feb;137(2):245-50. ISI 2,3
  8. ROKITANSKY ASCHOFF SINUSES INVOLMENT IN EARLY GALLBLADDER  CARCINOMA AS A PROGNOSTIC FACTOR.  A CONCURRENT COHORT STUDY Roa JC, Tapia O, Manterola C, Villaseca M, Guzman P, Araya JC, Bagci P, Saka B, Adsay V. Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor Virchows Arch. 2013 Nov;463(5):651-61. ISI 2,676
  9. [FREQUENCY OF CHLAMYDIA TRACHOMATIS INFECTION IN A GROUP OF WOMEN FROM REGION OF ARAUCANÍA, CHILE]. Silva R, León D, Viscarra T, Ili C, Roa JC, Sánchez R, Guzmán P, Brebi PRev Chilena Infectol. 2013 Dec;30(6):611-5. ISI 0,497
  10. CRITERIA FOR PATHOLOGIC SAMPLING OF GALLBLADDER SPECIMENS. Adsay V, Saka B, Basturk O, Roa JC, Renshaw A, Gould E. Am J Clin Pathol. 2013 Aug;140(2):278-80. ISI 2,6
  11. EXOME SEQUENCING REVEALS FREQUENT INACTIVATING MUTATIONS IN CHROMATIN REMODELING GENES IN INTRAHEPATIC CHOLANGIOCARCINOMAS BUT NOT IN GALLBLADDER CARCINOMAS Yuchen Jiao*, Timothy M. Pawlik*, Robert A. Anders*, Florin Selaru, Mirte M. Streppel, Anirban Maitra, Pedram Argani, G. Johan A. Offerhaus, Juan Carlos Roa, Victor E. Velculescu, Ralph H. Hruban, Bert Vogelstein, Kenneth W. Kinzler+, Nickolas Papadopoulos+, and  Laura D. Wood  Nat Genet. 2013 Nov 3. doi: 10.1038/ng.2813. ISI  35,2.
  12. AKT/MTOR SUBSTRATE P70S6K IS FREQUENTLY PHOSPHORYLATED IN GALLBLADDER CANCER TISSUE AND CELL LINES. Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC Onco Targets Ther. 2013 Oct 3;6:1373-84 ISI 2.07
  13. VIRULENCE OF INFECTING HELICOBACTER PYLORI STRAINS AND AMOUNT OF MONONUCLEAR CELL INFILTRATION ARE ASSOCIATED WITH LEVELS OF DNA HYPERMETHYLATION IN GASTRIC MUCOSAE Schneider BG, Piazuelo MB, Sicinschi LA, Mera R, Peng DF, Roa JC, Romero-Gallo J, Delgado AG, de Sablet T, Bravo LE, Wilson KT, El-Rifai W, Peek RM Jr, Correa P.Epigenetics. 2013 Nov;8(11):1153-61. ISI 4,5.
  14. SILAC-BASED QUANTITATIVE PROTEOMIC ANALYSIS OF GASTRIC CANCER SECRETOME. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar NR, Katte TV, Pinto SM, Srikanth SM, Kumar P, Pawar H, Kashyap MK, Maharudraiah J, Ashktorab H, Smoot DT, Ramaswamy G, Kumar RV, Cheng Y, Meltzer SJ, Roa JC, Chaerkady R, Prasad TS, Harsha HC, Chatterjee A, Pandey A.. Proteomics Clin Appl. 2013 Jun;7(5-6):355-66.  ISI 2,925.  
  15. PROGESTERONE RECEPTOR ASSEMBLY OF A TRANSCRIPTIONAL COMPLEX ALONG WITH AP-1, STAT3 AND ERBB-2 GOVERNS BREAST CANCER GROWTH AND PREDICTS RESPONSE TO ENDOCRINE THERAPY”, Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo RC,Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, MercoglianoMF, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV Breast Cancer Res. 2013 Dec 17;15(6):R118. [Epub ahead of print] PubMed PMID BCR (ISI 5.87)
  16. PERFIL DE METILACIÓN DE GENES SUPRESORES DE TUMORES APAF1, ASSP1, P73 Y FHIT EN PACIENTES CON LEUCEMIA LINFOBLÁSTICA AGUDA INFANTIL  ANGÉLICA Melo, Carmen Gloria Artigas, Sergio Muñoz, Priscilla Brebi, Rene Hoffstetter, Juan Carlos Roa  Int Journal Of Morphology 31 (3) : 973-79 ISI 0,213
  17. HUMAN PAPILLOMAVIRUS INFECTION IN MEN AND ITS RELATION WITH CANCER: CURRENT STATUS AND PROSPECTICS.Priscilla Brebi M.ab, Ricardo Hartley B.a,Carmen G. Iliab,Juan Carlos Roa S.bc, Raúl Sánchez G.a,Revista Internacional de Andrologia 11 (1) 2013 :25-30. ISI 0.220 
  18. [DETECTION OF HUMAN PAPILLOMA VIRUS INFECTION IN MEN]Silva R, León D, Brebi P, Ili C, Roa JC, Sánchez R. . Rev Chilena Infectol. 2013 Apr;30(2):186-92.doi: 10.4067/S0716-10182013000200009. Review. Spanish. PubMed PMID: 23677157.  ISI 0,497

 

Año 2012 

  1. .- Clinical and public health research using methylated DNA Immunoprecipitation (MeDIP): A comparison of commercially available kits to examine differential DNA methylation across the genome.Brebi-Mieville P, Ili-Gangas C, Leal-Rojas P, Noordhuis MG, Soudry E, Perez J, Roa JC, Sidransky D, Guerrero-Preston R.- Epigenetics. 2012 Jan 1;7(1).. ISI 4.6
  2. 4CLINICAL RELEVANCE OF ERBB-2/HER2 NUCLEAR EXPRESSION IN BREAST CANCER. Roxana Schillaci1, Pablo Guzmán González2, Florencia Cayrol1, Wendy Beguelin1, María C. Díaz Flaqué1, Cecilia J. Proietti1,Juan C. Roa Strauch2, Viviana Pineda Nesbet3, Jorge Palazzi4, Isabel Frahm5, Eduardo H. Charreau1, Patricia V. Elizalde1 BMC 2012 Feb 22;12:74. ISI 3,1
  3. GENE EXPRESSION PROFILING OF GASTRIC CANCER : Marimuthu A, Jacob HKC, Jakharia A, Subbannayya Y, Keerthikumar S, et al. (2011) Gene Expression Profiling of Gastric Cancer. J Proteomics Bioinform 2012 4: 074-082. doi:10.4172/jpb.1000170  NO ISI
  4. OVEREXPRESSION OF RIBOSOME BINDING PROTEIN 1 (RRBP1) IN BREAST CANCER. Telikicherla D, Marimuthu A, Kashyap MK, Ramachandra YL, Mohan S, Roa JC,  Maharudraiah J, Pandey A. Clin Proteomics. 2012 Jun 18;9(1):7. doi: 10.1186/1559-0275-9-7. NO ISI 
  5. OVEREXPRESSION OF KINESIN ASSOCIATED PROTEIN 3 (KIFAP3) IN BREAST CANCER. Deepthi T, Jagadeesha M, Harsh P, Arivusudar M, Manoj Kumar K, et al. (2012) . J Proteomics Bioinform 5: 122-126. doi:10.4172/jpb.1000223 No ISI
  6. EPIGENETIC ALTERATIONS IN PRENEOPLASTIC AND NEOPLASTIC LESIONS OF UTERINE CERVIX Kathleen Saavedra P.1, a, b, Priscilla Brebi M 1, a and Juan Carlos Roa S1, 2. Clin Epigenetics. 2012 Aug 31;4(1):13.  ISI6,22
  7. DNA PROMOTER METHYLATION AS A DIAGNOSTIC AND THERAPEUTIC BIOMARKER IN GALLBLADDER CANCER Letelier P, Brebi P, Tapia O, Roa JC.. Clin Epigenetics. 2012 Jul 13;4(1):11. ISI 6,22
  8. INTRACHOLECYSTIC PAPILLARY-TUBULAR NEOPLASMS (ICPN) OF THE GALLBLADDER (NEOPLASTIC POLYPS, ADENOMAS, AND PAPILLARY NEOPLASMS THAT ARE ≥1.0 CM):CLINICOPATHOLOGIC AND IMMUNOHISTOCHEMICAL ANALYSIS OF 123 CASES. Adsay V, Jang KT, Roa JC, Dursun N, Ohike N, Bagci P, Basturk O, Bandyopadhyay S, Cheng JD, Sarmiento JM, Escalona OT, Goodman M, Kong SY, Terry P. Am J Surg Pathol. 2012 Sep;36(9):1279-301.   ISI 4,4
  9. «MUCINOUS CARCINOMAS OF THE GALLBLADDER: CLINICOPATHOLOGIC ANALYSIS OF 15 CASES IDENTIFIED IN 606 CARCINOMAS» Dursun N, Escalona OT, Roa JC, Basturk O, Bagci P, Cakir A, Cheng J, Sarmiento J, Losada H, Kong SY, Ducato L, Goodman M, Adsay NV. Arch Pathol Lab Med. 2012 Nov;136(11):1347-58  ISI 2.3
  10. PATHOLOGIC STAGING OF PANCREATIC, AMPULLARY, BILIARY, AND GALLBLADDER CANCERS: PITFALLS AND PRACTICAL LIMITATIONS OF THE CURRENT AJCC/UICC TNM STAGING SYSTEM AND OPPORTUNITIES FOR IMPROVEMENT Adsay NV, Bagci P, Tajiri T, Oliva I, Ohike N, Balci S, Gonzalez RS, Basturk O, Jang KT, Roa JC. Semin Diagn Pathol. 2012 Aug;29(3):127-41. ISI 1.612 

Año 2011 (12)

  1. HPV GENOTYPING FROM CERVICAL INTRAEPITHELIAL NEOPLASIA IN CHILE. Carmen G. Ili a, Priscilla Brebi a, Jaime López a, Patricia García a, Pamela Leal a, Eugenio Suarezb, Juan C. Roa a*. J Med Virol. 2011 May;83(5):833-7. doi: 10.1002/jmv.22057. Epub 2011 Feb 25. ISI 2.9
  2. SQUAMOUS CELL AND ADENOSQUAMOUS CARCINOMAS OF THE GALLBLADDER: CLINICOPATHOLOGICAL ANALYSIS OF 34 CASES JC Roa1O, Tapia1, A Cakir2, I Coban2, N Dursun2, O Basturk3, H. Losada1, J     Sarmiento2 and NV Adsay2. Mod Pathol. 2011 Aug;24(8):1069-78.  ISI 4.2
  3. WIDESPREAD HYPOMETHYLATION OCCURS EARLY AND SYNERGIZES WITH GENE AMPLIFICATION DURING ESOPHAGEAL CARCINOGENESIS. Hector Alvarez1, Joanna Opalinska5*, Li Zhou5*, Davendra Sohal5, Melissa J. Fazzari6, Yiting Yu5, Christina Montagna5, Elizabeth A. Montgomery1, Marcia Canto2, Kerry B. Dunbar2, Jean Wang2, Juan Carlos Roa10 Yongkai Mo5, Tushar Bhagat5, K.H. Ramesh7, Linda Cannizzaro5, Jan Mollenhauer11, Reid F. Thompson5, Masako Suzuki5, Stephen Meltzer2, Ari Melnick, John M. Greally9, Anirban Maitra1,3,4, Amit Verma5 . PLoS Genet. 2011 Mar;7(3):e1001356. Epub 2011 Mar 31. Erratum in: PLoS Genet. 2011 May;7(5). ISI 9.5
  4. HYALINIZING CHOLECYSTITIS AND ASSOCIATED CARCINOMAS: CLINICOPATHOLOGIC ANALYSIS OF A DISTINCTIVE VARIANT OF CHOLECYSTITIS WITH PORCELAIN-LIKE FEATURES AND ACCOMPANYING DIAGNOSTICALLY CHALLENGING CARCINOMAS.Samip Patel1, Juan Carlos Roa2, Oscar Tapia2, Nevra Dursun3, Olca Basturk4, Asli Cakir1, Hector Losada5, Juan Sarmiento6, N. Volkan Adsay1Am J Surg Pathol. 2011 Aug;35(8):1104-13 ISI 4,1
  5. HPV DETECTION AND GENOTYPING IN PRENEOPLASTIC AND NEOPLASTIC LESIONS OF CERVIX UTERINE.. Jaime López M.1, Carmen Gloria Ili G.1, Priscilla Brebi M. 1, Patricia García M.1, Pamela Leal R.1, Marcelo Garcés C.1, Italo Capurro V. 3, Pablo Guzmán G. 1, 2, José Manuel Ojeda F. 4, Eugenio Suárez P. 5 y Juan Carlos Roa S.1, 2 méd. Chile, Nov 2010, vol.138, no.11, p.1343-1350. ISSN 0034-9887. ISI 0.37
  6. HIDATIDOSIS DE LA MAMA: REPORTE DE UN CASO Y REVISIÓN DE LA LITERATURA Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S. Rev Chil Cir, Oct 2010, vol.62, no.5, p.516-519. ISSN 0718-4026 ISI 0,2
  7. GLEASON SCORE IN PROSTATE CANCER. CORRELATION BETWEEN CORE BIOPSY AND RADICAL PROSTATECTOMY. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S  Rev Med Chil. 2011 Feb;139(2):171-6. Epub 2011 Jul 11 ISI 0.37
  8. GALLBLADDER CARCINOSARCOMA: A CASE REPORT AND REVIEW OF LITERATURA. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Rev Chil Cir, Feb 2011, vol.63, no.1, p.76-80. ISSN 0718-4026. ISI 0.2
  9. MORPHOLOGICAL PROGNOSTIC FACTORS IN GASTRIC CANCER PATIENTS  Juan Carlos Roa S 1, Oscar Tapia E1, Carlos Manterola D2, 3, Miguel Villaseca H1, Juan Carlos Araya O1,  Pablo Guzmán G1 Rev Chil Cir, Abr 2011, vol.63, no.2, p.154-161. ISSN 0718-4026 ISI 0.2
  10. MORPHOLOGICAL PROGNOSTIC FACTORS IN EARLY GASTRIC CANCER. Oscar Tapia E  Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Rev Chil Cir, Abr 2011, vol.63, no.2, p.162-169. ISSN 0718-4026 ISI 0.2
  11. MORPHOLOGICAL AND CLINICAL PROGNOSTIC FACTORS OF GASTRIC CANCER WITHOUT LYMPHATIC INVOLMENT (pN0):. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa Rev Med Chil. 2011 Apr;139(4):432-8. Epub 2011 Aug 25 ISI 0.37
  12. CANCER DE LA VESICULA BILIAR: ESTUDIOS NECESARIOS PARA EL DISEÑO DE ESTRATEGIAS DE PREVENCION Y DIAGNOSTICO Juan Carlos Roa S, Catterina Ferreccio,Juan Francisco Miquel. Revista Medica Clínica Las Condes 2011;22(4)486-91. NO ISI

 

Año 2010

  1. THE AXL RECEPTOR TYROSINE KINASE REGULATES THE RAL GTPASE PATHWAY AND ACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY Translational Implications for Disease Progression and Therapeutic Resistance in Barrett-associated Esophageal AdenocarcinomaAlvarez H, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A.  Cancer Biol Ther. 2010 Nov 4;10(10). ISI 2.9
  2. CANCER OF COLON AND RECTUM: MORPHOLOGICAL AND CLINICAL DESCRIPTION OF 322 CASES. Oscar Tapia E, Juan Carlos Roa S, Carlos Manterola D, Enrique Bellolio J. Int. J. Morphol., 28(1):2010. ISI 0.36
  3. HIDATIDOSIS DE LA MAMA: REPORTE DE UN CASO Y REVISIÓN DE LA LITERATURA. Oscar Tapia E, Viviana Pineda N, Juan Carlos Roa S.Aceptado Rev. Chilena de Cirugía. Vol 62 – Nº 5, 2010. ISI 0.2
  4. HUMAN PAPILLOMAVIRUS Genotyping in cervical adenovcarcinoma in the region of la Araucania-Chile. Angélica Melo A., Patricia García M., Italo Capurro V., Pablo Guzmán G. y Juan Carlos Roa Rev Chil Infectol  2010;(4):297-301 ISI 36
  5. DUODENAL VILLOUS ATROPHY ASSOCIATED WITH MYCOPHENOLATE MOFETIL: REPORT OF ONE CASE. Oscar Tapia E, Miguel Villaseca H, Armando Sierralta Z, Juan Carlos Roa S. Rev Med Chil. 2010 May;138(5):590-4 ISI 37
  6. GASTRIC CANCER IN CHILE. CLINICAL AND MORPHOLOGICAL VARIABLES IN A TWO PERIODS  COHORT (1986-1995 VS. 1996-2005) ESTUDIO DE COHORTE.  Oscar Tapia E, Juan Carlos Roa S, Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G.      Chil de Cir. Vol 62 – Nº 2, Abril 2010; pág. 125-130   ISI 0.2
  7. Morphological prognostic factors in Malignant melanoma of skin a 13 years follow up period. Enrique Bellolio J, Alvaro San Martín L, Luis Quiñiñir S, Juan Orellana C, Oscar Tapia E, Patricio Rifo, Juan Carlos Roa S, Miguel Villaseca H. Rev Chil  Vol 62 – Nº 3, June 2010. ISI 0.2
  8. MORPHOLOGICAL AND CLINICAL PROGNOSTIC FACTORS OF APENNDIX CARCINOMAS. A COHORT STUDY. Oscar Tapia E, Carlos Manterola D, Miguel Villaseca H, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S.Rev Chil  Vol 62 – Nº 3, June 2010 ISI 0.2
  9. HIDATIDOSIS ÓSEA: REPORTE DE 5 CASOS Y REVISIÓN DE LA LITERATURA. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Enviado Revista Médica de Chile. méd. Chile, Nov 2010, vol.138, no.11, p.1414-1421 ISI 0.37
  10. PRIMARY CUTANEOUS MUCORMICOSIS A two cases report study and literature review. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Submitted to Rev med Chil (June 2/2010) ISI 0.37
  11. HALLAZGOS MORFOLÓGICOS EN CASOS FATALES DE SÍNDROME CARDIOPULMONAR POR HANTAVIRUS. ESTUDIO DE 7 AUTOPSIAS Pablo Guzmán G., Oscar Tapia E., Miguel Villaseca H., Juan Araya O., Lilia Antonio P., Bolívar Lee O. y Juan Roa S. Rev Chil Infect 2010; 27 (5): 398-405. ISI 0.36
  12. BELLOLIO J ENRIQUE, SAN MARTÍN L ALVARO, QUIÑIÑIR S LUIS, ORELLANA C JUAN, TAPIA E OSCAR, RIFO L PATRICIO et al . Evaluación de factores histológicos pronósticos de sobrevida en melanoma maligno cutáneo, seguimiento de 13 años. Rev Chil Cir  [revista en Internet]. 2010  Ago [citado  2011  Abr  12] ;  62(4): 331-338 ISI 0.2
  13. SURVIVAL OF A COHORT OF PATIENTS WITH INTERMEDIATE AND ADVANCED GALL BLADDER CANCER TREATED WITH A PROSPECTIVE THERAPEUTIC PROTOCOL. Manterola C, Vial M, Roa JC. Acta Cir Bras 2010;25:225-230. ISI 0.5
  14. GASTRIC SIGNET CELL CARCINOMA: A PROGNOSTIC AND MORPHOLOGICAL COMPARISON WITH OTHER HISTOLOGICAL TYPES. Oscar Tapia E  Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S. Rev Chil Cir, Oct 2010, vol.62, no.5, p.458-464. ISSN 0718-402 ISI 0.2
  15. GALLBLADDER CARCINOSARCOMA : A CASE REPORT AND REVIEW OF LITERATURa.. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Submitted to Rev Cir Chil (april 23th/2010). ISI 0.2
  16. PRIMARY CUTANEOUS MUCORMICOSIS A two cases report study and literature review. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Submitted to Rev med Chil (June 2/2010) ISI 0.37
  17. MORPHOLOGICAL AND CLINICAL PROGNOSTIC FACTORS  OF APENNDIX CARCINOMAS. A COHORT STUDY. Oscar Tapia E, Carlos Manterola D, Miguel Villaseca H, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S.Rev Chil  Cir. Vol 62 – Nº 3, June 2010 ISI 0.2

Libros y Patentes:

  1. MOLECULAR PATHOLOGY OF LIVER DISEASES, P Monga, ed Ch. 63: «Molecular Pathology of Neoplasms of Extrahepatic Bile Ducts»   Nora Katabi, Juan Carlos Roa, and N. Volkan Adsay  Springer                         2011  Hardcover, ISBN 978-1-4419-7106-7 pages 881-890
  2. MOLECULAR PATHOLOGY OF  LIVER DISEASES, P Monga, ed Ch. 64: «Neoplasms of the Gallbladder» Juan Carlos Roa, Nora Katabi, and Volkan Adsay. Springer New York Hardcover, ISBN 978-1-4419-7106-7. Pages 891-905
  3. New Research on Precancerous Conditions. Editors: Jennifer E. Litchfield. PRENEOPLASTIC LESIONS OF A GALLBLADDER FROM MORPHOLOGICAL AND MOLECULAR POINTS OF VIEW. Juan Carlos Roa MD.   Iván Roa MD. Nova editorial 2007 US New York  ISBN: 1-60021-552-1
  4. Tumor Markers Research Focus. Editors: Deborah H. Chang SPECIFIC GENE METHYLATION AS A GASTROINTESTINAL TUMOR MARKER.Juan Carlos Roa1,  Miguel Villaseca1 Nova editorial  2007 US New York ISBN: 1-60021-544-0
  5. DNA Methylation Research Trenes. Editors: Taku B. Kobayashi METHYLATION IN CANCER RESEARCH Juan Carlos Roa S.  and Patricia García M. Nova editorial  2007 US New York ISBN: 1-60021-721-4
  6. Research Focus on Gastric Cancer Editors: Dorothy C. CardinniFUTURE DIRECTIONS IN GASTRIC CANCER RESEARCH Juan Carlos Roa S.  and Pamela Leal  . Nova editorial 2008    ISBN: 1-60021-726-5 US New York
  7. CIRUGIA PANCREATICA   Roa J. Capitulo de biologia molecular del cancer de Páncreas. Sociedad de Cirujanos de Chile. ISBN 956-291-536-0. pag 163-171   CHILE 2002.
  8. CIRUGIA DEL HIGADO VIA BILIAR Y  PANCREAS Consideraciones generales y genetico-moleculares del cáncer de los conductos biliares y de la vesícula biliar. Sociedad de Cirujanos de Chile. ISBN 956-7416-04-4.  pag 38-56 2005. CHILE.
  9. NOSE AND VIRAL CANCER: ETIOLOGY, PATHOGENESIS AND TREATMENT EDITORS: Aloisio Medeiros and Carlitos Veloso «Viral Cancers: Etiology, Pathogenesis, and Treatment.»   Priscilla Brebi Carmen Gloria ILI  Jaime Lopez  Juan Carlos Roa Nova editorial 2009 US New York  ISBN: 978-1-60741-735-4.
  10. MOLECULAR GENETIC ALTERATIONS IN PRENEOPLASTIC AND NEOPLASTIC LESIONS OF THE GALLBLADDER IN “FIELD CANCERIZATION: BASIC SCIENCE AND CLINICAL APPLICATIONS” . Juan Carlos Roa 1 and Jonathan Castillo 2 Nova editorial 2011 US New York  ISBN 978-1-61761-006-6 pages 241-275
  11. MOLECULAR GENETICS OF GALLBLADDER CANCER in «molecular pathology of organ systems for pathologists»  Roa J, Adsay V. Springer In press 2012.
  12. MOLECULAR GENETICS OF GALLBLADDER CANCER.In: eLS. Espinoza, Jaime A; García, Patricia; Bizama, Carolina; and Roa, Juan C John Wiley & Sons, Ltd: Chichester. (March 2015) 

 

Patentes

1.-Novel Genes and uses thereof, expresion profile of colon, gastric and pancreatic  61/404,141  ( USA)  2011.

2.- Kit de deteccion y genotipificacion de HPV. “HPV easy typing”

NÚMERO DE TRAMITACIÓN 765-2015  ( INAPI) via PCT

Síguenos también en:

Pontificia Universidad Católica de Chile 2019

Optimizado para: Internet Explorer 11, Microsoft Edge 44, Firefox 62, Chrome 68, Safari 11 o superiores.